⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
APRE News
Aprea Therapeutics, Inc. Common stock
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
globenewswire.com
APRE
Form 8-K
sec.gov
APRE
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
globenewswire.com
APRE
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
globenewswire.com
APRE
Form 8-K
sec.gov
APRE
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
globenewswire.com
APRE
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
globenewswire.com
APRE
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
globenewswire.com
APRE
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
globenewswire.com
APRE
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
globenewswire.com
APRE